Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.57 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.52 |
| ▸ | POU2F2 | P09086 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | POU2F1 | P14859 | 1/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.52 |
| ▸ | HRH2 | P25021 | 1/20 | 0.52 |
| ▸ | MC4R | P32245 | 1/20 | 0.52 |
| ▸ | FAP | Q12884 | 1/20 | 0.52 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.52 |
| ▸ | GHSR | Q92847 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8283505 | 0.92 | DPP4 (0.58) | DPP4CHRM1DPP9POU2F2ADORA3 | |
| SCHEMBL14045540 | 0.92 | DPP4 (0.52) | DPP4CHRM1CYP3A4 | |
| SCHEMBL4812485 | 0.88 | DPP4 (0.68) | DPP4CHRM1CYP3A4 | |
| SCHEMBL4812463 | 0.88 | DPP4 (0.68) | DPP4CHRM1CYP3A4 | |
| SCHEMBL4812678 | 0.88 | DPP4 (0.64) | DPP4CHRM1CYP3A4 | |
| SCHEMBL4812848 | 0.85 | DPP4 (0.67) | DPP4CHRM1FAP | |
| SCHEMBL4812831 | 0.85 | DPP4 (0.67) | DPP4CHRM1FAP | |
| SCHEMBL4815740 | 0.84 | DPP4 (0.55) | DPP4CHRM1 | |
| SCHEMBL8284589 | 0.83 | DPP4 (0.57) | DPP4CHRM1 | |
| SCHEMBL4807130 | 0.83 | DPP4 (0.68) | DPP4CHRM1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432262-B2 | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-07 | — | — | US | disclosed |
| US-7432262-B2 | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-07 | — | — | US | disclosed |
| US-7393847-B2 | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2008-07-01 | — | — | US | disclosed |
| US-7393847-B2 | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2008-07-01 | — | — | US | disclosed |
| US-20070142383-A1 | Imidazopyridazinediones, Their Preparation And Their Use As Pharmaceutical Compositions | ECKHARDT MATTHIAS | 2007-06-21 | — | — | US | disclosed |
| US-20070142383-A1 | Imidazopyridazinediones, Their Preparation And Their Use As Pharmaceutical Compositions | ECKHARDT MATTHIAS | 2007-06-21 | — | — | US | disclosed |
| US-20050203095-A1 | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142383-A1 | Imidazopyridazinediones, Their Preparation And Their Use As Pharmaceutical Compositions | DPP4, DPP3, DPP7 | DPP4 1/4885CHRM1 624/4885DPP9 4/4885 |
| US-20050203095-A1 | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | DPP4 1/4885CHRM1 611/4885DPP9 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.